射血分数保留心衰中的左室肥厚与心肌纤维化:机制与治疗
该综述阐述射血分数保留心衰(HFpEF)中左室肥厚与心肌纤维化的病理生理作用。HFpEF占心衰近半数,常合并高血压、肥胖或糖尿病,近半数患者存在左室肥厚或向心性重构。纤维化导致舒张僵硬度增加和充盈压升高,与运动耐量下降和预后不良相关,但目前尚无仅针对纤维化和肥厚的循证治疗。
要点
- HFpEF占心衰近半数,常合并高血压、肥胖或糖尿病等多重心代谢疾病。
- 近半数HFpEF患者存在左室肥厚或向心性重构,纤维化致舒张僵硬度增加和充盈压升高。
- 目前尚无仅针对心肌纤维化和左室肥厚的循证治疗,需开发新靶点。
核心结论
- 心肌纤维化和左室肥厚是HFpEF异质性病理生理的关键特征,可能为未来临床试验提供有前景的靶点。
研究设计与样本
- 综述,检索范围未在摘要中报告。
主要发现
- HFpEF占所有心衰病例近半数,具有表型异质性且多重心代谢疾病高发。
- 高血压、肥胖或糖尿病等合并症通过多种血流动力学和代谢损伤参与不良心脏重构和心肌纤维化。
- 近半数HFpEF患者存在左室肥厚或向心性重构。
- 心肌纤维化及其左室结构和几何替代改变导致舒张僵硬度增加和充盈压升高,与运动耐量下降和预后不良相关。
临床怎么用
- 识别心肌纤维化和左室肥厚作为HFpEF关键特征,可能有助于开发未来临床试验靶点。
局限性
- 摘要未报告综述的检索范围或纳入研究的具体信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Heart failure with preserved ejection fraction (HFpEF) accounts for nearly half of all heart failure cases and is characterized by phenotypical heterogeneity with a high prevalence of multiple, often overlapping cardiometabolic disorders. Comorbidities such as hypertension, obesity, or diabetes are present in many HFpEF patients and are hypothesized to contribute to adverse cardiac remodelling and myocardial fibrosis through a variety of haemodynamic and metabolic impairments, with nearly half of all HFpEF patients exhibiting left ventricular (LV) hypertrophy or concentric remodelling. Myocardial fibrosis and its surrogate changes in LV structure and geometry lead to functional impairments such as increased diastolic stiffness and elevated filling pressures and are associated with reduced exercise tolerance and poor prognosis in patients with HFpEF. Despite recent therapeutic progress, there are currently no evidence-based therapies mechanistically focusing solely on myocardial fibrosis and LV hypertrophy in HFpEF. Recognizing myocardial fibrosis and LV hypertrophy as key features of the heterogeneous HFpEF pathophysiology may contribute to the development of promising targets for future clinical trials. This review elaborates on the pathophysiological role of fibrotic remodelling and LV hypertrophy in HFpEF, outlines contemporary diagnostic standards, and discusses emerging therapeutic strategies, aiming at directly modulating myocardial fibrosis and hypertrophy in HFpEF.
引用
- Peikert, Fontana, Solomon, et al. Left ventricular hypertrophy and myocardial fibrosis in heart failure with preserved ejection fraction: mechanisms and treatment. Eur Heart J. 2026. PMID: 40892534. doi:10.1093/eurheartj/ehaf524
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。